BERGISCH GLADBACH, Germany – September 22, 2010 - RI Research Instruments GmbH, a majority-owned subsidiary of Bruker Energy & Supercon Technologies, Inc. (BEST), today announced the award of a 24.9 Million Euro contract from DESY (Deutsches Elektronen-Synchrotron) in Hamburg, Germany for the supply of 300 superconducting radio frequency (srf) accelerator cavities for the European XFEL (X-Ray Free Electron Laser) facility.

According to published reports, the European XFEL is expected to generate ultra-short X-ray flashes 27,000 times per second, with a brilliance that is a billion times higher than that of the best conventional X-ray radiation sources. As a result of these characteristics, which are considered unique worldwide, the facility is expected to open completely new research opportunities for scientists and industrial users.

The contract received by RI Research Instruments covers the manufacturing, surface preparation and integration into a helium vessel of 300 srf cavities ordered by DESY. RI's advanced srf cavities use thin-walled Niobium metallic superconductor structures which are bonded together using specialized electron beam welding manufacturing technology in order to achieve ultra-low electrical losses and very high quality factors Q. Superconducting rf cavities can provide unique scientific capabilities because they can accelerate electrons with higher electromagnetic fields at higher duty cycles that would cause conventional, non-superconducting rf cavities, e.g. made of copper, to melt.

The European XFEL is designed with a 17.5 GeV linear accelerator which will use srf cavities to deliver electron bunches for the generation of X-ray flashes in a special arrangements of magnets, called undulators. After completion of a small number of pre-series srf cavities in 2011, BEST expects series deliveries to start at the beginning of 2012 and last until 2014. In terms of Euro value, this is the largest order in the 50-year history of Bruker Corporation, the parent company of BEST. DESY is expected to require additional srf cavities for XFEL in the future.

Dr. Michael Peiniger, Managing Director of RI Research Instruments, commented: "This award represents the largest contract on superconducting rf cavities ever received in RI's (formerly ACCEL Instruments) history. This XFEL contract fits perfectly as a continuation of our more than 1,000 srf cavities produced in the past 20 years for research labs like JLAB, SNS/ORNL, Stanford, Cornell University, Frankfurt University, FNAL, DESY, CERN, GANIL, and many others worldwide."

Hanspeter Vogel, Director of RI, added: "This contract marks a new milestone as, for the first time, industry will perform the final clean room preparation of the XFEL srf cavities, with corresponding investments in chemistry and clean room technology, giving the DESY XFEL lab the advantage of being able to perform cryogenic rf power testing on the cavities immediately after delivery. We believe this contract will further enhance our reputation as a leader in srf cavities."

About RI Research Instruments and Bruker Energy & Supercon Technologies, Inc.:
RI Research Instruments GmbH is a world leader in the development and manufacturing of normal and superconducting rf cavities and systems, linear accelerators, as well as special products for physics and energy research, scientific, medical and industrial applications. RI products also include high-performance electron and ion sources, particle beamlines and diagnostics, research reactor subunits as well as vacuum and cryogenic systems. BEST has operations in the US, the UK and Germany, and is a wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR).

For more information, please visit: www.research-instruments.de or www.bruker-est.com


Cautionary statement of best

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "continue" or other similar words.

These forward-looking statements are predictions, not guarantees. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to materially differ from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those projected, include, but are not limited to, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as guarantees of future events.

The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.


Cautionary statement of Bruker Corporation

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

RI Research Instruments Contact:

Dr. Michael Peiniger
Managing Director, RI Research Instruments
Tel: +49 2204 843676
Email: michael.peiniger@research-instruments.de

Hanspeter Vogel
Director, RI Research Instruments
Tel: +49 2204 843513
Email: hanspeter.vogel@research-instruments.de